What is the appropriate dosing regimen for hydrazine (hydrazine sulfate) in medical treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hydralazine Dosing for Medical Treatment

For hypertension management, initiate oral hydralazine at 25-50 mg three to four times daily, titrating upward to a maximum of 200-300 mg total daily dose divided throughout the day. 1, 2

Initial Dosing Strategy

Starting Dose

  • Begin with 25 mg three times daily for most patients with hypertension 1, 2
  • For pediatric patients: start at 0.75 mg/kg/day divided into four doses (QID), with maximum of 7.5 mg/kg/day up to 200 mg/day 1
  • When transitioning from IV to oral therapy in acute settings: 25-50 mg orally, repeatable every 4-6 hours as needed 2

Titration Protocol

  • Increase dose every 2-4 weeks based on blood pressure response 1, 2
  • Target dose for resistant hypertension: 25 mg three times daily initially, titrating upward to maximum dose 1
  • Do not increase if symptomatic hypotension develops 1

Context-Specific Dosing

Heart Failure with Reduced Ejection Fraction

  • Fixed-dose combination: hydralazine 37.5 mg + isosorbide dinitrate 20 mg three times daily as starting dose 1
  • Target dose: hydralazine 75 mg + isosorbide dinitrate 40 mg three times daily (total daily hydralazine 225 mg) 1
  • Mean achieved dose in clinical trials: approximately 175 mg total daily 1, 2
  • Alternative regimen: 25-50 mg hydralazine three to four times daily, up to 300 mg total daily in divided doses 1

Resistant Hypertension (Step 5 Therapy)

  • Start at 25 mg three times daily after optimizing other antihypertensive classes 1
  • Titrate upward to maximum tolerated dose 1
  • This is reserved for patients who have failed: RAS blocker, calcium channel blocker, thiazide-like diuretic, mineralocorticoid receptor antagonist, and beta-blocker 1

Maximum Dosing Limits

  • Absolute maximum: 300 mg total daily dose 1, 2
  • Pediatric maximum: 200 mg/day 1
  • Most common maintenance range: 100-300 mg daily in divided doses 2

Critical Timing Considerations

  • Onset of action: 10-30 minutes after oral administration (slower than IV) 2
  • Duration of effect: 2-4 hours, necessitating multiple daily doses 2
  • Administer three to four times daily to maintain consistent blood pressure control 1, 2

Important Clinical Caveats

Common Adverse Effects

  • Tachycardia and fluid retention are expected and often require concomitant beta-blocker and diuretic therapy 1
  • Risk of drug-induced lupus-like syndrome in slow acetylators with prolonged use 1
  • Monitor for arthralgia, muscle aches, joint swelling, pericarditis, pleuritis, rash, or fever suggesting lupus-like syndrome 1

Contraindications and Monitoring

  • Requires concomitant use of beta-blocker and diuretic to prevent reflex tachycardia and fluid retention 1
  • Less desirable as first-line agent for acute hypertension due to unpredictable response and prolonged duration 2
  • Reserved for resistant hypertension or specific populations (e.g., African-American patients with heart failure) 1

When to Escalate Therapy

  • If blood pressure remains uncontrolled on maximum hydralazine dose (300 mg/day), substitute minoxidil 2.5 mg two to three times daily and consider referral to hypertension specialist 1

Note: The FDA-labeled drug "hydrazine" 3 refers to hydroxyzine (an antihistamine/anxiolytic), which is an entirely different medication from hydralazine. The research on hydrazine sulfate 4, 5, 6, 7, 8 pertains to an industrial chemical and unproven cancer therapy with significant hepatotoxicity risk—this is NOT the same as hydralazine and should never be confused in clinical practice.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Oral Hydralazine Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The question of carcinogenic effects of hydrazine.

Experimental pathology, 1988

Research

Hydrazine sulfate: a current perspective.

Nutrition and cancer, 1987

Research

Studies on hydrazine hepatotoxicity. 2. Biochemical findings.

Journal of toxicology and environmental health, 1982

Research

Fatal hepatorenal failure associated with hydrazine sulfate.

Annals of internal medicine, 2000

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.